Pharmacokinetics of anticancer drugs, plasmid DNA, and their delivery systems in tissue-isolated perfused tumors

Advanced Drug Delivery Reviews

Volumn 40, Issue 1-2, 1999, Pages 19-37

  Nishikawa, Makiya ^a   Hashida, Mitsuru ^a  

^a Grad Sch Pharmaceutical Sci   (Japan)

Author keywords

Cancer; Chemotherapy; Drug delivery system; Gene therapy; Intratumoral injection; Perfusion experiment; Pharmacokinetics; Tissue isolated tumor

Indexed keywords

CHEMOTHERAPY; DNA; DRUG INFUSION; ELECTRIC CHARGE; LIPIDS; MACROMOLECULES; MOLECULAR WEIGHT; ONCOLOGY; PHARMACOKINETICS;

GENE THERAPY;

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; DEXTRAN; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; INULIN; LIPOSOME; MITOMYCIN C; PLASMID DNA;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; COMPLEX FORMATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; EMULSION; GENE THERAPY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; LIPOPHILICITY; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE PERFUSION;

EID: 0032874450     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00038-1     Document Type: Article

References (87)

1. Hunt C.A., MacGregor R.D., Siegel R.A. Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharm. Res. 3:1986;333-344.
2. Sezaki H., Hashida M. Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst. 1:1984;1-38.
3. Sezaki H., Takakura Y., Hashida M. Soluble macromolecular carriers for the delivery of antitumour drugs. Adv. Drug Deliv. Rev. 3:1989;247-266.
4. Juliano R.L. Drug Delivery System, Characterization and Biomedical Applications. 1980;Oxford University Press, New York.
5. Gregoriadis G., Senior J., Trouet A. Targeting of Drugs. 1982;Plenum Press, New York.
6. Douglas S.J., Davis S.S., Illum L. Nanoparticles in drug delivery. CRC Crit. Rev. Ther. Drug Carrier Syst. 3:1987;233-261.
7. Daoud S.S., Hume L.R., Juliano R.L. Liposomes in cancer therapy. Adv. Drug Deliv. Rev. 3:1989;405-418.
8. Bennett H.S., Luft J.H., Hampton J.C. Morphological classification of vertebrate blood capillaries. Am. J. Physiol. 196:1959;381-390.
9. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:1987;559-593.
10. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 48:1988;2641-2658.
11. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:1989;570-576.
12. Jam R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 4:1998;655-657.
13. Fujimori K., Covell D.G., Fletcher J.E., Weinstein J.N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors. Cancer Res. 49:1989;5656-5663.
14. Juweid M., Neumann R., Paik C., Perez-Bacete M.J., Sato J., Van Osdol W., Weinstein J.N. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52:1992;5144-5153.
15. Saga T., Neumann R.D., Heya T., Sato J., Kinuya S., Le N., Paik C.H., Weinstein J.N. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc. Natl. Acad. Sci. USA. 92:1995;8999-9003.
16. Roth J.A., Cristiano R.J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 89:1997;21-39.
17. Gullino P.M., Grantham F.H. Studies on the exchanges of fluids between host and tumor. I. A method for growing 'tissue-isolated' tumors in laboratory animals. J. Natl. Cancer Inst. 27:1961;679-689.
18. Gullino P.M. Influence of blood supply on thermal properties and metabolism of mammary carcinomas. Ann. NY Acad. Sci. 335:1980;1-21.
19. Kristjansen P.E., Roberge S., Lee I., Jain R.K. Tissue-isolated human tumor xenografts in athymic nude mice. Microvasc. Res. 48:1994;389-402.
20. Sevick E.M., Jain R.K. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Res. 49:1989;3506-3512.
21. Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50:1990;4478-4484.
22. 31P NMR. Proc. Natl. Acad. Sci. USA. 90:1993;2646-2650.
23. Jain R.K., Baxter L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48:1988;7022-7032.
24. Sevick E.M., Jain R.K. Blood flow and venous pH of tissue-isolated Walker 256 carcinoma during hyperglycemia. Cancer Res. 48:1988;1201-1207.
25. Gullino P.M., Grantham F.H. The vascular space of growing tumors. Cancer Res. 24:1964;1727-1732.
26. Song C.W., Levitt S.H. Quantitative study of vascularity in Walker carcinoma 256. Cancer Res. 31:1971;587-589.
27. Ohkouchi K., Imoto H., Takakura Y., Hashida M., Sezaki H. Disposition of anticancer drugs after bolus arterial administration in a tissue-isolated tumor perfusion system. Cancer Res. 50:1990;1640-1644.
28. Warren B.A. The ultrastructure of the microcirculation at the advancing edge of Walker 256 carcinoma. Microvasc. Res. 2:1970;443-453.
29. Leunig M., Yuan F., Menger M.D., Boucher Y., Goetz A.E., Messmer K., Jain R.K. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma L5174T in SCID mice. Cancer Res. 52:1992;6553-6560.
30. Fox S.B., Gatter K.C., Bicknell R., Going J.J., Stanton P., Cooke T.G., Harris A.L. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res. 53:1993;4161-4163.
31. Butler T.P., Grantham F.H., Gullino P.M. Bulk transfer of fluid in the interstitial compartment of mammary tumours. Cancer Res. 35:1975;3084-3088.
32. Saikawa A., Nomura T., Yamashita F., Takakura Y., Sezaki H., Hashida M. Pharmacokinetic analysis of drug disposition after intratumoral injection in a tissue-isolated tumor perfusion system. Pharm. Res. 13:1996;1438-1444.
33. Nugent L.J., Jain R.K. Extravascular diffusion in normal and neoplastic tissues. Cancer Res. 44:1984;238-244.
34. Heuser L.S., Miller A.F. Differential macromolecular leakage from the vasculature of tumors. Cancer. 57:1986;461-464.
35. Kakutani T., Suematsu Y., Cheah W.Y., Sumimoto E., Hashida M. Disposition characteristics of lipophilic mitomycin C prodrug in an intraarterial muscle infusion system. Chem. Pharm. Bull. 35:1987;4898-4906.
36. Kakutani T., Atsumi R., Sumimoto E., Hashida M. Deconvolution analysis of the regeneration process of mitomycin C from prodrug in a muscle perfusion system based on statistical moment theory. Chem. Pharm. Bull. 35:1987;4907-4914.
37. Yamaoka K., Nakagawa T., Uno T. Statistical moments in pharmacokinetics. J. Pharmacokin. Biopharm. 6:1978;547-558.
38. Cutler D.J. Theory of the mean absorption time, an adjunct to conventional bioavailability studies. J. Pharm. Pharmacol. 30:1978;476-478.
39. Kakutani T., Yamaoka K., Hashida M., Sezaki H. A new method for assessment of drug disposition in muscle: application of statistical moment theory to local perfusion systems. J. Pharmacokin. Biopharm. 13:1985;609-631.
40. Weiss M. Moments of physiological transit time distributions and the time course of drug disposition in the body. J. Math. Biol. 15:1982;305-318.
41. Seymour L.W. Passive tumour targeting of soluble macromolecules and drug conjugates. CRC Crit. Rev. Ther. Drug Carrier Syst. 9:1992;135-187.
42. Duncan R., Spreafico F. Polymer conjugates: pharmacokinetic considerations for design and development. Clin. Pharmacokin. 27:1994;290-306.
43. Takakura Y., Takagi A., Hashida M., Sezaki H. Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharm. Res. 4:1987;293-300.
44. Takakura Y., Atsumi R., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular injection. Int. J. Pharm. 37:1987;145-154.
45. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 7:1990;339-346.
46. O'Connor S.W., Bale W.F. Accessibility of circulating immunoglobulin G to the extravascular compartments of solid rat tumors. Cancer Res. 44:1984;3719-3723.
47. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:1986;6387-6392.
48. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res. 47:1987;3039-3051.
49. Imoto H., Sakamura Y., Ohkouchi K., Atsumi R., Takakura Y., Sezaki H., Hashida M. Disposition characteristics of macromolecules in the perfused tissue-isolated tumor preparation. Cancer Res. 52:1992;4396-4401.
50. Sato K., Itakura K., Nishida K., Takakura Y., Hashida M., Sezaki H. Disposition of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugates in the perfused rat liver. J. Pharm. Sci. 78:1989;11-16.
51. Nishida K., Tonegawa C., Nakane S., Takakura Y., Hashida M., Sezaki H. Effect of electric charge on the hepatic uptake of macromolecules in the rat liver. Int. J. Pharm. 65:1990;7-17.
52. Nishida K., Mihara K., Takino T., Nakane S., Takakura Y., Hashida M., Sezaki H. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm. Res. 8:1991;437-444.
53. Swabb E.A., Wei J., Gullino P.M. Diffusion and convection in normal and neoplastic tissues. Cancer Res. 34:1974;2814-2822.
54. Hashida M., Takakura Y., Matsumoto S., Sasaki H., Kato A., Kojima K., Muranishi S., Sezaki H. Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity. Int. J. Pharm. 37:1983;135-143.
55. Knepp W.A., Jayakrishnan A., Quigg J.M., Sitren H.S., Bagnall J.J., Goldberg E.P. Synthesis, properties, and intratumoral evaluation of mitoxantrone-loaded casein microspheres in Lewis lung carcinoma. J. Pharm. Pharmacol. 45:1993;887-891.
56. Landrito J.E., Yoshiga K., Sakurai K., Takada K. Effects of intralesional injection of cisplatin on squamous cell carcinoma and normal tissue of mice. Anticancer Res. 14:1994;113-118.
57. Zbar B., Bernstein I.D., Bartlett G.L., Hanna M.G., Rapp H.J. Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J. Natl. Cancer Inst. 49:1972;119-130.
58. McLaughlin C.A., Cantrell J.L., Ribi E., Goldberg E.P. Intratumor chemoimmunotherapy with mitomycin C and components from mycobacteria in regression of line 10 tumors in guinea pigs. Cancer Res. 38:1978;1311-1316.
59. Kanellos J., Mckenzie I.F.C., Pietersz G.A. Intratumor therapy of solid tumours with ricin-antibody conjugates. Immunol. Cell Biol. 67:1989;89-99.
60. Balemans L.T.M., Mattijssen V., Steerenberg P.A., Van Driel B.E.M., De Mulder P.H.M., Den Otter W. Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity. Cancer Immunol. Immunother. 37:1993;7-14.
61. Ebina T., Murata K., Tamura K. Antitumor effects of intratumoral administration of biological response modifiers: induction of immunosuppressive acidic protein, a type of α1-acid glycoprotein, in mice. Jpn. J. Cancer Res. 85:1994;93-100.
62. Kitajima I., Shinohara T., Minor T., Bibbs L., Bilakovics J., Nerenberg M. Human T-cell leukemia virus type 1 tax transformation is associated with increased uptake of oligodeoxynucleotides in vitro and in vivo. J. Biol. Chem. 267:1992;25881-25888.
63. Ratajczak M.Z., Kant J.A., Luger S.M., Hijiya N., Zhang J., Zon A., Gewirtz A.M. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 89:1992;11823-11827.
64. Plautz G.E., Yang Z., Wu B., Gao X., Huang L., Nabel G.J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA. 90:1993;4645-4649.
65. Sun W.H., Burkholder J.K., Sun J., Culp J., Turner J., Lu X.G., Pugh T.D., Ershler W.B., Yang N.S. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc. Natl. Acad. Sci. USA. 92:1995;2889-2893.
66. Wei M.X., Tamiya T., Hurford R.K. Jr., Boviatsis E.J., Tepper R.I., Chiocca E.A. Enhancement of interleukin-4-mediated tumor regression in athymic mice by in situ retroviral gene transfer. Gene Ther. 6:1995;437-443.
67. Toloza E.M., Hunt K., Swisher S., McBride W., Lau R., Pang S., Rhoades K., Drake T., Belldegrun A., Glaspy J., Economou J.S. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther. 3:1996;11-17.
68. Dow S.W., Elmslie R.E., Willson A.P., Roche L., Gorman C., Potter T.A. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J. Clin. Invest. 101:1998;2406-2414.
69. Nomura T., Koreeda N., Yamashita F., Takakura Y., Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm. Res. 15:1998;128-132.
70. Nomura T., Nakajima S., Kawabata K., Yamashita F., Takakura Y., Hashida M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res. 57:1997;2681-2686.
71. Nomura T., Saikawa A., Morita S., Sakaeda (ne Kakutani) T., Yamashita F., Honda K., Takakura Y., Hashida M. Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoral injection. J. Control. Rel. 52:1998;239-252.
72. Nishikawa M., Takakura Y., Hashida M. Biofate of fat emulsions. Benita S. Submicron Emulsions in Drug Targeting and Delivery. 1998;99-118 Harwood Academic Publishers, Amsterdam.
73. Allen T.M., Moase E.H. Therapeutic opportunities for targeted liposomal drug delivery. Adv. Drug Deliv. Rev. 21:1996;117-133.
74. Collins-Gold L.C., Lyons R.T., Bartholow L.C. Parenteral emulsions for drug delivery. Adv. Drug Deliv. Rev. 5:1990;189-208.
75. Davis S.S., Illum L. Colloidal delivery systems - opportunity and challenges. Tomlinson E., Davis S.S. Site-Specific Drug Delivery. 1986;93-110 John Wiley & Sons, Ltd, New York.
76. Torchilin V.P. Liposomes as targetable drug carriers. CRC Crit. Rev. Ther. Drug Carrier Syst. 2:1985;65-115.
77. Anderson P.M., Katsanis E., Leonard A.S., Schow D., Loeffler C.M., Goldstein M.B., Ochoa A.C. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res. 50:1990;1853-1856.
78. Vaage J., Mayhew E. Immunotherapy of a mouse mammary carcinoma by sustained peritumor release of IL-2. Int. J. Cancer. 47:1991;582-585.
79. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:1994;3352-3356.
80. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53:1993;3765-3770.
81. Huang S.K., Lee K.D., Hong K., Friend D.S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52:1992;5135-5143.
82. Oku N., Namba Y., Okada S. Tumor accumulation of novel RES-avoiding liposomes. Biochim. Biophys. Acta. 1126:1992;255-260.
83. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464.
84. Honda K., Satomura K., Hashida M., Sezaki H. Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C. Jpn. J. Cancer Chemother. 12:1985;530-535.
85. Satomura K., Honda K., Arimoto A., Kikuchi S., Sezaki H., Hashida M. Surgical chemotherapy using mitomycin C-dextran conjugate. Ther. Res. (Tokyo). 2:1985;311-317.
86. Takakura Y., Kitajima M., Matsumoto S., Hashida M., Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumour activities. Int. J. Pharm. 37:1987;135-143.
87. Takakura Y., Matsumoto S., Hashida M., Sezaki H. Physicochemical properties and antitumour activities of polymeric prodrugs of mitomycin C with different regeneration rates. J. Control Rel. 10:1989;97-105.